Jean Michel Pignon

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

Rémy Gressin, Nicolas Daguindau, Adrian Tempescul et al. · Haematologica · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot, Hyacinthe Johnson‐Ansah, Françoise Huguet et al. · Blood · 2015 · 33 citations

Medicine, Oncology, Pharmacology +14

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Delphine Réa, Franck E. Nicolini, Michel Tulliez et al. · Blood · 2014 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +8

Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group

Rémy Gressin, Mary Callanan, Nicolas Daguindau et al. · Blood · 2014 · 22 citations

Medicine, Geriatric Medicine, Oncology +3

Exhaustive analysis of the P53 gene coding sequence by denaturing gradient gel electrophoresis: Application to the detection of point mutations in acute leukemias

Jean Michel Pignon, Isabelle Vinatier, Pascale Fanen et al. · Human Mutation · 1994 · 21 citations

Medicine, Genetics, Hematology +15